Articolo L’altra medicina N. 108 – 08-09/2021
Bibliografia
- Abu-Shanab A1, Quigley EM.
The role of the gut microbiota in nonalcoholic fatty liver disease.
Nat Rev Gastroenterol Hepatol. 2010 Dec;7(12):691-701. doi: 10.1038/nrgastro.2010.172. Epub 2010 Nov
2. Bajaj JS1, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy Gastroenterology. 2011 Feb;140(2):478-487.
- Farrell GC1, van Rooyen D, Gan L, Chitturi S. .NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications Gut Liver. 2012 Apr;6(2):149-71. doi: 10.5009/gnl.2012.6.2.149. Epub 2012 Apr 17.
- Gupta A1, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y.
Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010 Nov;53(5):849-55. doi: 10.1016/j.jhep.2010.05.017. Epub 2010 Jul 17. - Baffy G, Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009 Jul;51(1):212-23
- Carlotta De Filippo et al.- Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33): 14691–14696. Published online 2010 Aug 2. doi: 10.1073/pnas.1005963107
PMCID: PMC2930426
Evolution ). - Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. Antonella Mosca, Valerio Nobili et al. Journal of Hepatology)
